198
22. Bouchemal K, Mazzaferro S (2012) How to
conduct and interpret ITC experiments accurately for cyclodextrin-guest interactions. Drug
Discov Today 17(11-12):623–629. https://
doi.org/10.1016/j.drudis.2012.01.023
23. Callies O, Hernandez Daranas A (2016)
Application of isothermal titration calorimetry
as a tool to study natural product interactions.
Nat Prod Rep 33(7):881–904. https://doi.
org/10.1039/c5np00094g
24. Thanassoulas A, Nounesis G (2019)
Isothermal titration calorimetry: a powerful tool for the characterization of molecular interactions. In: Demetzos C, Pippa N
(eds) Thermodynamics and biophysics of
biomedical nanosystems: applications and
practical considerations. Springer Singapore,
Singapore,
pp 63–103.
https://doi.
org/10.1007/978-981-13-0989-2_4
25. Cooper A, Johnson CM, Lakey JH et al
(2001) Heat does not come in different
colours: entropy-enthalpy compensation, free
energy windows, quantum confinement, pressure perturbation calorimetry, solvation and
the multiple causes of heat capacity effects
in biomolecular interactions. Biophys Chem
93(2–3):215–230
26. Rekharsky
MV,
Inoue
Y
(2006)
Microcalorimetry. In: Cyclodextrins and
their complexes, pp 199–230. https://doi.
org/10.1002/3527608982.ch8
27. Liu L, Guo Q-X (2002) The driving forces
in the inclusion complexation of cyclodextrins. J Inclusion Phenomena Macrocyclic
Chem 42(1):1–14. https://doi.org/10.102
3/A:1014520830813
28. Rekharsky MV, Inoue Y (1998) Complexation
thermodynamics of cyclodextrins. Chem Rev
98(5):1875–1918
29. Asgharzadeh F, Hassanian SM, Ferns GA
et al (2018) The therapeutic potential of
angiotensin- converting enzyme and angiotensin receptor inhibitors in the treatment of
colorectal cancer: rational strategies and recent
progress. Curr Pharm Des 24(39):4652–4658.
https://doi.org/10.2174/13816128256661
90111145140
30. Shen H, Gao Q, Ye Q et al (2018) Peritumoral
implantation of hydrogel-containing nanoparticles and losartan for enhanced nanoparticle penetration and antitumor effect. Int J
Nanomedicine 13:7409–7426. https://doi.
org/10.2147/IJN.S178585
31. Coulson R, Liew SH, Connelly AA et al
(2017) The angiotensin receptor blocker,
Losartan, inhibits mammary tumor development and progression to invasive carcinoma.
Oncotarget 8(12):18640–18656. https://doi.
org/10.18632/oncotarget.15553
32. Xia T, He Q, Shi K et al (2018) Losartan
loaded liposomes improve the antitumor efficacy of liposomal paclitaxel modified with pH
sensitive peptides by inhibition of collagen in
breast cancer. Pharm Dev Technol 23(1):13–
21. https://doi.org/10.1080/10837450.201
6.1265553
33. Lo MW, Goldberg MR, McCrea JB et al
(1995) Pharmacokinetics of losartan, an
angiotensin II receptor antagonist, and its
active metabolite EXP3174 in humans. Clin
Pharmacol Ther 58(6):641–649. https://doi.
org/10.1016/0009-9236(95)90020-9
34. Elmowafy E, Soliman ME (2019) Losartanchitosan/dextran sulfate microplex as a carrier
to lung therapeutics: dry powder inhalation,
aerodynamic profile and pulmonary tolerability.
Int J Biol Macromol 136:220–229. https://
doi.org/10.1016/j.ijbiomac.2019.06.058
35. Hu C, Liu X, Ran W et al (2017) Regulating
cancer associated fibroblasts with losartanloaded injectable peptide hydrogel to potentiate chemotherapy in inhibiting growth and
lung metastasis of triple negative breast cancer. Biomaterials 144:60–72. https://doi.
org/10.1016/j.biomaterials.2017.08.009
36. De Paula WX, Denadai AML, Braga ANG et al
(2018) A long-lasting oral preformulation of
the angiotensin II AT1 receptor antagonist
losartan. Drug Dev Ind Pharm 44(9):1498–
1505. https://doi.org/10.1080/03639045.2
018.1467923
37. Hsu CM, Yu SC, Tsai FJ et al (2019)
Characterization of in vitro and in vivo bioactivity of a ferulic acid-2-hydroxypropyl-betacyclodextrin inclusion complex. Colloids Surf
B Biointerfaces 180:68–74. https://doi.
org/10.1016/j.colsurfb.2019.04.020
38. Schonbeck C, Westh P, Madsen JC et al (2010)
Hydroxypropyl-substituted beta-cyclodextrins:
influence of degree of substitution on the
thermodynamics of complexation with tauroconjugated and glycoconjugated bile salts.
Langmuir 26(23):17949–17957. https://doi.
org/10.1021/la103124n
39. de Paula WX, Denadai AM, Santoro MM et al
(2011) Supramolecular interactions between
losartan and hydroxypropyl-beta-CD: ESI
mass-spectrometry, NMR techniques, phase
solubility, isothermal titration calorimetry and
anti-hypertensive studies. Int J Pharm 404(1–
2):116–123.
https://doi.org/10.1016/j.
ijpharm.2010.11.008
Maria V. Chatziathanasiadou et al.
22. Bouchemal K, Mazzaferro S (2012) How to
conduct and interpret ITC experiments accurately for cyclodextrin-guest interactions. Drug
Discov Today 17(11-12):623–629. https://
doi.org/10.1016/j.drudis.2012.01.023
23. Callies O, Hernandez Daranas A (2016)
Application of isothermal titration calorimetry
as a tool to study natural product interactions.
Nat Prod Rep 33(7):881–904. https://doi.
org/10.1039/c5np00094g
24. Thanassoulas A, Nounesis G (2019)
Isothermal titration calorimetry: a powerful tool for the characterization of molecular interactions. In: Demetzos C, Pippa N
(eds) Thermodynamics and biophysics of
biomedical nanosystems: applications and
practical considerations. Springer Singapore,
Singapore,
pp 63–103.
https://doi.
org/10.1007/978-981-13-0989-2_4
25. Cooper A, Johnson CM, Lakey JH et al
(2001) Heat does not come in different
colours: entropy-enthalpy compensation, free
energy windows, quantum confinement, pressure perturbation calorimetry, solvation and
the multiple causes of heat capacity effects
in biomolecular interactions. Biophys Chem
93(2–3):215–230
26. Rekharsky
MV,
Inoue
Y
(2006)
Microcalorimetry. In: Cyclodextrins and
their complexes, pp 199–230. https://doi.
org/10.1002/3527608982.ch8
27. Liu L, Guo Q-X (2002) The driving forces
in the inclusion complexation of cyclodextrins. J Inclusion Phenomena Macrocyclic
Chem 42(1):1–14. https://doi.org/10.102
3/A:1014520830813
28. Rekharsky MV, Inoue Y (1998) Complexation
thermodynamics of cyclodextrins. Chem Rev
98(5):1875–1918
29. Asgharzadeh F, Hassanian SM, Ferns GA
et al (2018) The therapeutic potential of
angiotensin- converting enzyme and angiotensin receptor inhibitors in the treatment of
colorectal cancer: rational strategies and recent
progress. Curr Pharm Des 24(39):4652–4658.
https://doi.org/10.2174/13816128256661
90111145140
30. Shen H, Gao Q, Ye Q et al (2018) Peritumoral
implantation of hydrogel-containing nanoparticles and losartan for enhanced nanoparticle penetration and antitumor effect. Int J
Nanomedicine 13:7409–7426. https://doi.
org/10.2147/IJN.S178585
31. Coulson R, Liew SH, Connelly AA et al
(2017) The angiotensin receptor blocker,
Losartan, inhibits mammary tumor development and progression to invasive carcinoma.
Oncotarget 8(12):18640–18656. https://doi.
org/10.18632/oncotarget.15553
32. Xia T, He Q, Shi K et al (2018) Losartan
loaded liposomes improve the antitumor efficacy of liposomal paclitaxel modified with pH
sensitive peptides by inhibition of collagen in
breast cancer. Pharm Dev Technol 23(1):13–
21. https://doi.org/10.1080/10837450.201
6.1265553
33. Lo MW, Goldberg MR, McCrea JB et al
(1995) Pharmacokinetics of losartan, an
angiotensin II receptor antagonist, and its
active metabolite EXP3174 in humans. Clin
Pharmacol Ther 58(6):641–649. https://doi.
org/10.1016/0009-9236(95)90020-9
34. Elmowafy E, Soliman ME (2019) Losartanchitosan/dextran sulfate microplex as a carrier
to lung therapeutics: dry powder inhalation,
aerodynamic profile and pulmonary tolerability.
Int J Biol Macromol 136:220–229. https://
doi.org/10.1016/j.ijbiomac.2019.06.058
35. Hu C, Liu X, Ran W et al (2017) Regulating
cancer associated fibroblasts with losartanloaded injectable peptide hydrogel to potentiate chemotherapy in inhibiting growth and
lung metastasis of triple negative breast cancer. Biomaterials 144:60–72. https://doi.
org/10.1016/j.biomaterials.2017.08.009
36. De Paula WX, Denadai AML, Braga ANG et al
(2018) A long-lasting oral preformulation of
the angiotensin II AT1 receptor antagonist
losartan. Drug Dev Ind Pharm 44(9):1498–
1505. https://doi.org/10.1080/03639045.2
018.1467923
37. Hsu CM, Yu SC, Tsai FJ et al (2019)
Characterization of in vitro and in vivo bioactivity of a ferulic acid-2-hydroxypropyl-betacyclodextrin inclusion complex. Colloids Surf
B Biointerfaces 180:68–74. https://doi.
org/10.1016/j.colsurfb.2019.04.020
38. Schonbeck C, Westh P, Madsen JC et al (2010)
Hydroxypropyl-substituted beta-cyclodextrins:
influence of degree of substitution on the
thermodynamics of complexation with tauroconjugated and glycoconjugated bile salts.
Langmuir 26(23):17949–17957. https://doi.
org/10.1021/la103124n
39. de Paula WX, Denadai AM, Santoro MM et al
(2011) Supramolecular interactions between
losartan and hydroxypropyl-beta-CD: ESI
mass-spectrometry, NMR techniques, phase
solubility, isothermal titration calorimetry and
anti-hypertensive studies. Int J Pharm 404(1–
2):116–123.
https://doi.org/10.1016/j.
ijpharm.2010.11.008
Maria V. Chatziathanasiadou et al.